share_log

里昂：重申国药控股(01099)“买入”评级 目标价降至27港元

Lyon: Reiterates Sinopharm Holdings' (01099) “Buy” Rating Target Price Reduced to HK$27

Zhitong Finance ·  Mar 26 22:58

The Zhitong Finance App learned that Lyon released a research report saying that Sinopharm Holdings (01099)'s performance in the final quarter of last year gradually improved, as the impact of mainland pharmaceutical corruption gradually subsided until the end of last year. At the end of last year, the company's revenue increased 3.9% quarterly, and net profit increased 48.5% quarterly to RMB 3 billion. The company focuses on profit expansion. It is expected that its emerging medical device manufacturing business will drive profit expansion and reaffirm the “buy” rating. The target price was slightly lowered from HK$27.1 to HK$27.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment